Catholic University of Sacred Heart, Rome, Italy.
Dipartimento Di Scienze Dell'Invecchiamento, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Neurologiche, Rome, Italy.
Neurol Sci. 2022 Aug;43(8):4635-4643. doi: 10.1007/s10072-022-06136-2. Epub 2022 May 24.
Evidence is emerging about an extra-pulmonary involvement of SARS-CoV-2, including the nervous system. Autonomic dysfunction in patients recovering from acute coronavirus disease 2019 (COVID-19) has been recently described. Dysautonomic symptoms have been reported in the acute phase of the disease, but clear evidence is lacking, especially in the non-critical forms of the infection.
The aim of this study is to assess the prevalence of dysautonomia in acute, non-critically ill COVID-19 patients.
In this observational, cross-sectional study, we compared 38 non-critically ill patients with acute COVID-19 (COVID + group) to 38 healthy volunteers (COVID - group) in order to assess the prevalence of signs and symptoms of dysautonomia through the administration of the composite autonomic symptom score 31 (COMPASS-31) and an active standing test. Comparisons between groups were performed by means of both univariate and multivariate analyses.
The prevalence of orthostatic hypotension was significantly higher in the COVID + group. Higher total scores of COMPASS-31 were observed in the COVID + group than controls. Significant differences between groups emerged in the secretomotor, orthostatic intolerance, and gastrointestinal COMPASS-31 domains. All these results maintained the statistical significance after the adjustment for concomitant drugs with a known effect on the autonomic nervous system assumed by the study participants, except for the differences in the gastrointestinal domain of COMPASS-31.
Our results suggest that an autonomic dysfunction could be an early manifestation of COVID-19, even in the contest of mild forms of the infection.
越来越多的证据表明,SARS-CoV-2 除了肺部受累外,还会累及神经系统。最近有研究报道,在从急性 2019 冠状病毒病(COVID-19)中康复的患者中存在自主神经功能障碍。自主神经症状在疾病的急性期已有报道,但缺乏明确的证据,特别是在感染的非危重型病例中。
本研究旨在评估急性非危重型 COVID-19 患者自主神经功能障碍的发生率。
在这项观察性、横断面研究中,我们比较了 38 例急性 COVID-19 非危重型患者(COVID+组)和 38 例健康志愿者(COVID-组),通过复合自主症状评分 31 项(COMPASS-31)和主动站立试验来评估自主神经功能障碍的体征和症状的发生率。通过单变量和多变量分析比较两组之间的差异。
COVID+组直立性低血压的发生率明显更高。与对照组相比,COVID+组 COMPASS-31 的总分更高。COMPASS-31 的分泌运动、直立不耐受和胃肠道领域在两组之间存在显著差异。在调整了研究参与者同时服用的已知对自主神经系统有影响的药物后,所有这些结果均保持统计学意义,除了 COMPASS-31 的胃肠道领域的差异。
我们的研究结果表明,自主神经功能障碍可能是 COVID-19 的早期表现,即使在感染的轻度病例中也是如此。